Sapheon Inc. has been acquired by Covidien plc
Sapheon Inc., based in Santa Rosa, California, has been acquired by the Irish Covidien plc, a global healthcare products leader dedicated to innovation and long-term growth. Financial details have not been disclosed.
Sapheon Inc. is a medical device company whose mission is to develop new approaches and disruptive technologies for the treatment of vascular disease. The company’s current focus is the VenaSeal Sapheon Closure System, a novel treatment for venous reflux disease. Sapheon, Inc. will operate as a subsidiary of Covidien plc.
Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Through its Medical Devices and Medical Supplies segments, the company creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence.
One of Oaklins' teams in the USA served as the exclusive financial advisor to the seller in this transaction.
Talk to the deal team
Michael S. Goldman
Oaklins TM Capital
James McLaren
Oaklins TM Capital
Related deals
Bluegem Capital Partners and AREV Partners have acquired 100% of Groupe Pinard
Bluegem Capital Partners and AREV Partners have successfully completed the acquisition of the prestigious Groupe Pinard from IK Partners.
Learn moreLumiforte partners with Kartesia to propel global growth and innovation
Lumiforte, a global leader in innovative smart coatings for greenhouse horticulture, sports line-marking and other functional coatings for agriculture and industry, is excited to announce an investment from Kartesia, a European specialist in capital solutions for small and medium-sized companies. Horticoop, a longstanding shareholder of Lumiforte and a key player in the horticultural industry through its investment cooperative, continues to remain a shareholder.
Learn morePanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production
PanTera, a Belgian radioisotope producer, has completed a US$104.1 million (€93 million) oversubscribed Series A fundraising round led by EQT Life Sciences. Additional equity and debt funding brings the total amount raised to US$150 million (€134 million). In addition to EQT Life Sciences, the Series A round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV.
Learn more